Ernie Bush, Ph.D., Vice President, Collaborative Projects, The Drug Safety Executive Council (DSEC)
James Cross, MS, Ph.D., Integrated Safety Risk Manager, Genentech, San Francisco, CA
James Dykens, Ph.D., Group Leader, Investigative Cell Toxicity, Drug Safety R&D, Pfizer, Inc.
Michael Forstner, M.Sc., Ph.D., Integrated Safety Risk Manager, F. Hoffmann-La Roche, Basel, Switzerland
Stephen Furlong, Ph.D., Safety Science Lead, US Patient Safety, AstraZeneca
Marwan Ghabril, Ph.D., Assistant Professor of Clinical Medicine, Gastroenterology/Hepatology, Indiana University
Ihor Gussak, M.D., Ph.D., FACC, Chief Medical Officer and Vice President, NewCardio, Inc.
Joanna Haas, M.D., Vice President, Global Patient Safety and Risk Management, Genzyme Corp.
Peter Hoffmann, M.D., Ph.D., Executive Director, Preclinical Safety, Novartis Institutes for BioMedical Research
Michael J. Klepper, M.D., former Founder and President of Integrated Safety Systems, Inc.; co-author of “Drug Safety Data”
Pierre Lainee, Ph.D., Principal Scientist, Preclinical Safety, AstraZeneca
Sandeep Modi, Ph.D., Cheminformatician, Safety & Environmental Assurance Centre, Unilever; former Research Associate, GlaxoSmithKline
- James Milligan, M.D., Safety Science Expert/Safety Physician, Clinical Safety, AstraZeneca
Aris Persidis, Ph.D., President, Biovista, Inc.
Arie Regev M.D., Chair, Liver and GI Safety Committee, Global Patient Safety, Eli Lilly & Company
Colette F. Saccomanno, Ph.D., MSLIS, Integrated Safety Risk Manager, F. Hoffmann-La Roche, Nutley, NJ
Phil Sager, M.D., Vice President, Clinical Research, Head, CV/Metabolic Clinical Development, Gilead
Anja Slikkerveer, M.D., Scientific Director, Translational Science, Drug Safety Research Laboratories, Astellas Pharma
Paul Watkins, M.D., Verne S. Caviness Distinguished Professor of Medicine, Professor of Pharmacotherapy, University of North Carolina Chapel Hill